Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-line platinum-based therapy with dostarlimab and niraparib versus standard of care in advanced non-mucinous epithelial ovarian cancer
2018-000413-20Phase 3Active
- Sponsor
- TESARO, Inc.
- Start
- Aug 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dostarlimab and niraparib in ovarian cancer and epithelial ovarian cancer (EOC) (2 arms), sponsored by TESARO, Inc. Primary endpoint: Progression-free survival in PD-L1-positive patients. Started Aug 2018; status: active.
02
Drugs
dostarlimabniraparib
03
Conditions
ovarian cancerepithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2018-000413-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000413-20.